Epilepsy, Partial

23 registered clinical trials studyying Epilepsy, Partial.

Status	Trial	Sponsor	Phase
Withdrawn	To Evaluate the Effect of Perampanel on Objective and Subjective Sleep in Subjects With Insomnia and Partial O NCT02220972	Eisai Inc.	Phase 4
Terminated	Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE) NCT01891890	Emory University	Phase 3
Withdrawn	Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian NCT01691872	GlaxoSmithKline	Phase 1
Terminated	IVIG Treatment for Refractory Immune-Related Adult Epilepsy NCT01545518	Emory University	Phase 2
Completed	Meta-Analysis Plan for Pooled Data for Studies VRX-RET-E22-303 and VRX-RET-E22-304 NCT01457989	GlaxoSmithKline	—
Terminated	Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide NCT01375374	UCB Pharma	Phase 3
Completed	An Observational Study to Assess the Burden of Drug-resistant Partial Epilepsy in Italy NCT01332539	GlaxoSmithKline	—
Completed	Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy NCT00280059	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Phase 3
Completed	Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy NCT00355082	GlaxoSmithKline	Phase 3
Completed	Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam NCT00152503	UCB Pharma SA	Phase 2
Completed	Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures NCT00152451	UCB S.A. - Pharma Sector	Phase 2
Completed	A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures. NCT00175890	UCB Pharma	Phase 3
Completed	Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures NCT00152516	UCB Pharma	Phase 3
Completed	Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Partia NCT00113165	GlaxoSmithKline	Phase 3
Completed	A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures NCT00105040	UCB Pharma	Phase 2
Completed	Double-blind, Placebo-controlled Study of Levetiracetam in Adults With POS NCT00152373	UCB Pharma	Phase 3
Completed	Open Label Safety and Efficacy Study of Levetiracetam in Korean Patients With Epilepsy NCT00160628	UCB Pharma	Phase 3
Completed	Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy NCT00160654	UCB Pharma	Phase 4
Completed	Determine Effects of Adjunctive Levetiracetam on Sleep Architecture in Adults With Partial Onset Epilepsy. NCT00245713	UCB Pharma	Phase 4
Completed	Pharmacovigilance Study of Keppra. SPAIN - SKATE : Safety of Keppra as Adjunctive Therapy in Epilepsy NCT00643500	UCB Pharma	Phase 4
Completed	Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method NCT00160615	UCB Japan Co. Ltd.	Phase 3
Completed	A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy NCT00150709	UCB Pharma	Phase 3
Completed	To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy. NCT00141414	Pfizer	Phase 2